We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is UnitedHealth Finding a Better Path to Medicare Advantage Growth?
Read MoreHide Full Article
Key Takeaways
UnitedHealth expects MA enrollment to fall by 1.1 million members as it exits unprofitable plans.
Medicare margins are expected above 3% in 2026 as pricing and benefit changes improve the membership mix.
UnitedHealth raised its 2026 adjusted EPS outlook to $19.50-$20 amid improving medical cost trends.
UnitedHealth Group Incorporated (UNH - Free Report) is taking a more disciplined approach to Medicare Advantage (MA), with profitability increasingly taking precedence over membership expansion. This shift comes as elevated medical costs continue to challenge the industry and pressure insurers to reassess pricing, benefits and market participation.
UnitedHealthcare expects 2026 MA enrollment to decline by approximately 1.1 million members, reflecting targeted exits from unprofitable plans. However, Medicare margins are now expected to finish the year above 3%. The improvement reflects tighter benefit design, pricing actions and a more favorable membership mix, while the company expects Medicare medical cost trends to come below the initial estimate of near 10%.
Cost-control initiatives are also becoming an important part of the strategy. Network curation, care management, affordability programs and greater use of value-based care are helping contain medical expenses. Favorable claims experience and a lighter respiratory season have provided additional support. UNH’s consolidated medical care ratio improved to 86.7% in the second quarter from 89.4% a year ago. The company raised its 2026 adjusted EPS outlook to $19.50-$20. For 2027, benefit planning remains centered on current cost trends, with adjustments to benefits and selective market participation aimed at maintaining margin stability.
The strategy could place UnitedHealth on a more sustainable MA growth path, even as near-term enrollment remains under pressure. Improving medical cost trends and a gradual recovery in membership could strengthen the economics of UnitedHealth’s MA business. If these trends persist, UNH could emerge from its current reset with a more profitable MA business and a stronger foundation for long-term growth.
Humana remains heavily exposed to Medicare Advantage, making medical cost control and benefit optimization critical to its outlook. HUM is focusing on pricing, network management and operating efficiencies to restore margins while navigating membership pressure and elevated utilization across its MA portfolio.
Elevance Health is sharpening its Medicare Advantage strategy by prioritizing profitable growth over broad membership gains. Portfolio repositioning, disciplined plan design and a stronger focus on D-SNP and HMO offerings are improving performance, while care management and favorable claims trends support ELV’s path toward at least a 2% operating margin in 2026.
Shares of UNH have gained 25.2% in the past year compared with the industry’s growth of 21.4%.
Image Source: Zacks Investment Research
From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 17.96, above the industry average of 15.60. UNH carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for UnitedHealth’s 2026 earnings is pegged at $19.69 per share, implying 20.4% growth from the year-ago period.
View the Zacks #1 Rank List
Image: Bigstock
Is UnitedHealth Finding a Better Path to Medicare Advantage Growth?
Key Takeaways
UnitedHealth Group Incorporated (UNH - Free Report) is taking a more disciplined approach to Medicare Advantage (MA), with profitability increasingly taking precedence over membership expansion. This shift comes as elevated medical costs continue to challenge the industry and pressure insurers to reassess pricing, benefits and market participation.
UnitedHealthcare expects 2026 MA enrollment to decline by approximately 1.1 million members, reflecting targeted exits from unprofitable plans. However, Medicare margins are now expected to finish the year above 3%. The improvement reflects tighter benefit design, pricing actions and a more favorable membership mix, while the company expects Medicare medical cost trends to come below the initial estimate of near 10%.
Cost-control initiatives are also becoming an important part of the strategy. Network curation, care management, affordability programs and greater use of value-based care are helping contain medical expenses. Favorable claims experience and a lighter respiratory season have provided additional support. UNH’s consolidated medical care ratio improved to 86.7% in the second quarter from 89.4% a year ago. The company raised its 2026 adjusted EPS outlook to $19.50-$20. For 2027, benefit planning remains centered on current cost trends, with adjustments to benefits and selective market participation aimed at maintaining margin stability.
The strategy could place UnitedHealth on a more sustainable MA growth path, even as near-term enrollment remains under pressure. Improving medical cost trends and a gradual recovery in membership could strengthen the economics of UnitedHealth’s MA business. If these trends persist, UNH could emerge from its current reset with a more profitable MA business and a stronger foundation for long-term growth.
How Are Competitors Faring?
Some of UNH’s major competitors in the medical space are Humana Inc. (HUM - Free Report) and Elevance Health, Inc. (ELV - Free Report) .
Humana remains heavily exposed to Medicare Advantage, making medical cost control and benefit optimization critical to its outlook. HUM is focusing on pricing, network management and operating efficiencies to restore margins while navigating membership pressure and elevated utilization across its MA portfolio.
Elevance Health is sharpening its Medicare Advantage strategy by prioritizing profitable growth over broad membership gains. Portfolio repositioning, disciplined plan design and a stronger focus on D-SNP and HMO offerings are improving performance, while care management and favorable claims trends support ELV’s path toward at least a 2% operating margin in 2026.
UnitedHealth’s Price Performance, Valuation & Estimates
Shares of UNH have gained 25.2% in the past year compared with the industry’s growth of 21.4%.
Image Source: Zacks Investment Research
From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 17.96, above the industry average of 15.60. UNH carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for UnitedHealth’s 2026 earnings is pegged at $19.69 per share, implying 20.4% growth from the year-ago period.
Image Source: Zacks Investment Research
UNH stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.